Moderna Says FDA Advisory Committee Unanimously Backs mRNA-1010 Seasonal Flu Vaccine For Adults 50–64 and 65+, Voting 9-0 That Benefits Outweigh Risks Ahead Of August 5 PDUFA Decision Date

FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026

CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 that the benefits of mRNA-1010, Moderna's investigational seasonal influenza vaccine, outweigh its risks for the prevention of influenza disease in adults 50 through 64 years of age and voted 9-0 that the benefits of mRNA-1010 outweigh its risks for the prevention of influenza disease in adults 65 years of age and older.